Indivior PLC
LSE:INDV
Indivior PLC
Revenue
Indivior PLC
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Indivior PLC
LSE:INDV
|
Revenue
$1.1B
|
CAGR 3-Years
19%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Revenue
£30.7B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
2%
|
|
AstraZeneca PLC
LSE:AZN
|
Revenue
$47.6B
|
CAGR 3-Years
20%
|
CAGR 5-Years
16%
|
CAGR 10-Years
6%
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Revenue
$2.9B
|
CAGR 3-Years
7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
8%
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Revenue
£761.5m
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
15%
|
See Also
What is Indivior PLC's Revenue?
Revenue
1.1B
USD
Based on the financial report for Mar 31, 2024, Indivior PLC's Revenue amounts to 1.1B USD.
What is Indivior PLC's Revenue growth rate?
Revenue CAGR 5Y
3%
Over the last year, the Revenue growth was 19%. The average annual Revenue growth rates for Indivior PLC have been 19% over the past three years , 3% over the past five years .